Enliven Therapeutics develops small molecule kinase inhibitors that enhance treatment efficacy and safety for cancer patients, specifically targeting resistance mechanisms and brain metastases. The company's therapies aim to improve both survival rates and quality of life for individuals facing cancer.
Funding
$90M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer treatments can be limited by resistance mechanisms, the spread of cancer to the brain (metastasis), and significant side effects, impacting both survival rates and the patient's quality of life. Current therapies may lack the selectivity needed to effectively target cancer cells while sparing healthy tissues, leading to toxicities and reduced efficacy.
Solution
Enliven Therapeutics develops small molecule kinase inhibitors designed to overcome resistance mechanisms, effectively target brain metastases, and improve the safety profile of cancer treatments. Their approach focuses on creating highly selective and combinable therapies that enhance efficacy while minimizing off-target effects. By addressing these key challenges, Enliven aims to improve both the survival rates and overall well-being of cancer patients. The company's kinase inhibitors are designed for better selectivity and combinability.
Target Audience
The primary target audience includes cancer patients, oncologists, and medical professionals seeking more effective and safer treatment options for various types of cancer.
Features
- Development of small molecule kinase inhibitors.
- Therapies designed to combat resistance mechanisms in cancer cells.
- Focus on addressing and treating brain metastases.
- Kinase inhibitors with enhanced selectivity for improved efficacy and reduced toxicity.
- Therapies designed for better combinability with other cancer treatments.